Dabrafenib and Tolazamide

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Dabrafenib may interfere with blood glucose control and reduce the effectiveness of TOLAZamide and other diabetic medications. Monitor your blood sugar levels closely. You may need a dose adjustment of your diabetic medications during and after treatment with dabrafenib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with dabrafenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4 and/or 2C9, including many antidiabetic agents such as nateglinide, repaglinide, linagliptin, saxagliptin, and sulfonylureas. Dabrafenib has been found in vitro and in vivo to be an inducer of CYP450 3A4 and 2C9 using the probe substrates midazolam and warfarin, respectively. Onset of induction is likely to occur after 3 days of repeat dosing with dabrafenib; however, transient inhibition of these isoenzymes may be observed during the first few days of treatment. According to the product labeling, hyperglycemia is a commonly reported side effect during treatment with dabrafenib, which may require dosage increases of insulin and oral hypoglycemic agents or initiation of such therapy. It is unclear whether dabrafenib itself can impair glucose metabolism, or if the hyperglycemia is primarily due to a pharmacokinetic interaction between dabrafenib and some antidiabetic agents.

MANAGEMENT: Caution is advised when dabrafenib is prescribed to patients with diabetes, particularly those receiving antidiabetic agents that are metabolized by CYP450 3A4 and/or 2C9. Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of dabrafenib, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination. Likewise, patients should be observed for hypoglycemia when dabrafenib is withdrawn from their therapeutic regimen.

Dabrafenib

Generic Name: dabrafenib

Brand name: Tafinlar

Synonyms: n.a.

What is Dabrafenib?

Tolazamide

Generic Name: tolazamide

Brand name: Tolinase

Synonyms: TOLAZamide

What is Tolazamide?